Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial

Authors: Els Tobback, Sophie Degroote, Sabine Buysse, Liesbeth Delesie, Lucas Van Dooren, Sophie Vanherrewege, Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, Elizaveta Padalko, Steven Callens, Marie-Angélique De Scheerder

Source: International Journal of Infectious Diseases, Vol 122, Iss , Pp 628-635 (2022)

Subject Terms: Camostat, COVID-19, Efficacy, Neutralizing antibodies, Randomized controlled trial, Safety, Infectious and parasitic diseases, RC109-216

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1201971222003885; https://doaj.org/toc/1201-9712

Access URL: https://doaj.org/article/b977e1e64d6b4df4897cb4a0ff30160f